MedTrace Logo

AME Study of [14C]-PC14586 in Healthy Male Participants

NCT05523687 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2022-12-20

No results posted yet for this study

Summary

This study will assess the PK and rates of elimination and mass balance of total radioactivity from \[14C\]-PC14586

Conditions

  • Healthy Male Volunteers

Interventions

DRUG

[14C]-PC14586

Single, oral dose of \[14C\]-PC14586

Sponsors & Collaborators

  • PMV Pharmaceuticals, Inc

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-06
Primary Completion
2022-11-30
Completion
2022-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05523687 on ClinicalTrials.gov